Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $8.5 million, an 11% increase from $7.6 million in Q1 2024 [7] - Gross margin improved to 60%, up from 59% in Q1 2024 [9] - Cash and cash equivalents decreased to $12.4 million from $20.1 million at the end of 2024 [10] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 9% to $4.7 million, driven by a $1.2 million increase in product revenue [7][8] - Neurosurgery Navigation revenue grew 70% to $3.3 million, attributed to higher sales of new product offerings [8] - Capital Equipment and Software revenue decreased 63% to $500,000 due to fewer new placements of navigation and laser units [9] Market Data and Key Metrics Changes - The company activated two new sites in Q1 2025, expanding its installed base [51] - The single-use consumables business saw a growth rate of 104%, driven by increased orders from biopharma partners [13] Company Strategy and Development Direction - The company aims to extend its lead in cell and gene therapy through a comprehensive drug delivery ecosystem [4] - Plans to evolve the product portfolio to enhance hospital efficiency and throughput [5] - The company is focused on expanding its global installed base and generating scale for novel treatments [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for additional cell and gene therapy platforms to gain approvals in the next two years [15] - The recent partnership with Overland Capital provides the company with foundational funding to execute its strategy [6][12] - Management anticipates that revenue growth will outpace expense growth for the full year [11][57] Other Important Information - The company has implemented a new subscription program called Pathfinder, allowing hospitals to access technology through annual fees [21] - The company expects to achieve GLP certification by the end of the year, which will enable larger studies and increased demand [42][47] Q&A Session Summary Question: What initiatives can be prioritized now that capital is available? - Management indicated opportunities to accelerate hiring for field support and preclinical resources to meet partner demands [29] Question: How does the new capital runway relate to achieving sustained breakeven? - Management believes the new debt facility can support cash breakeven, with expectations of generating meaningful cash flow in the coming years [31] Question: How is the neuro franchise tracking relative to expectations? - Management stated that the neuro franchise is on plan and expects significant growth throughout the year [34] Question: What is the expected mix of MRI versus OR procedures in the future? - Management anticipates a shift towards more OR procedures, but expects MRI procedures to remain crucial for drug delivery therapies [40][41] Question: What is the status of GLP certification and customer interest? - Management confirmed that they are on track for GLP certification and have received interest from pharma partners for studies once certified [42][46] Question: How are the new sites placed in terms of sales agreements? - Management clarified that the two new sites activated were capital placements, with additional systems placed under the Pathfinder agreements [51][52]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $8.5 million, an 11% increase from $7.6 million in Q1 2024 [7] - Gross margin improved to 60%, up from 59% in Q1 2024 [9] - Cash and cash equivalents decreased to $12.4 million from $20.1 million at the end of 2024 [10] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 9% to $4.7 million, driven by a $1.2 million increase in product revenue [7][8] - Neurosurgery Navigation revenue grew 70% to $3.3 million, attributed to higher sales of new product offerings [8] - Capital Equipment and Software revenue decreased 63% to $500,000 due to fewer new placements of navigation and laser units [9] Market Data and Key Metrics Changes - The company activated two new sites in Q1 2025, expanding its installed base [19][50] - The single-use consumables business saw a growth rate of 104%, driven by increased orders from biopharma partners [13] Company Strategy and Development Direction - The company aims to extend its lead in cell and gene therapy through a comprehensive drug delivery ecosystem [4] - Plans to evolve the product portfolio to enhance hospital efficiency and throughput [5] - The company is focused on expanding its global installed base and generating scale for novel treatments [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for additional cell and gene therapy platforms to gain regulatory approval within two years [15] - The recent partnership with Overland Capital provides the company with foundational funding to execute its strategy [6][12] - Management anticipates that revenue growth will outpace expense growth for the full year [11][56] Other Important Information - The company has implemented a new subscription program called Pathfinder, allowing hospitals to access technology through an annual fee [21] - The Pathfinder program will smooth out capital revenue recognition over time [22] Q&A Session Summary Question: Opportunities with Incremental Capital - Management sees opportunities to accelerate hiring and expand preclinical resources in response to pharma partners' requests [29] Question: Neuro Franchise Growth Expectations - Management believes the neuro franchise can grow significantly more than 20% throughout the year, with potential upside based on product adoption [33] Question: MRI vs. OR Procedure Mix - Management anticipates a shift towards more procedures being performed in the operating room, especially as new drug therapies are introduced [39] Question: GLP Certification Timeline - Management expects to achieve GLP certification by the end of the year, with pent-up demand from pharma partners for studies once certified [42][44]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $8.5 million, an 11% increase from $7.6 million in Q1 2024 [7] - Gross margin improved to 60%, up from 59% in Q1 2024 [10] - Cash and cash equivalents decreased to $12.4 million from $20.1 million at the end of 2024 [11] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 9% to $4.7 million, driven by a $1.2 million increase in product revenue [8] - Neurosurgery Navigation revenue surged 70% to $3.3 million, attributed to higher sales of new product offerings [9] - Capital Equipment and Software revenue fell 63% to $500,000 due to fewer new placements of navigation and laser units [10] Market Data and Key Metrics Changes - The company activated two new sites in Q1 2025, which were both capital placements [51] - The introduction of the three point zero navigation software has allowed expansion into operating rooms, enhancing market reach [14] Company Strategy and Development Direction - The company aims to extend its lead in cell and gene therapy through a comprehensive drug delivery ecosystem [4] - Plans to evolve the product portfolio to focus on fast, simple, and predictable workflows to increase hospital efficiency [5] - The company is pursuing global scale by expanding its installed base and generating more access to its ecosystem [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for additional cell and gene therapy platforms to gain approvals in the next two years [16] - The recent partnership with Overland Capital provides the company with the necessary funding to execute its strategy [6] - Management anticipates that operational cash burn will continue to increase but expects to generate meaningful cash flow as new drugs come online [31] Other Important Information - The company has implemented a Pathfinder subscription program to smooth capital revenue recognition over time [22] - The three point zero navigation software has been well received, with positive feedback from surgeons regarding efficiency and accuracy [18] Q&A Session Questions and Answers Question: Are there initiatives that can be prioritized now with access to incremental capital? - Management confirmed that there are opportunities to accelerate hiring and expand preclinical resources in response to partner requests [29] Question: How does the new capital runway relate to achieving sustained breakeven? - Management believes the new debt facility can support the company towards cash breakeven, especially with the flexibility of an interest-only period [31] Question: How is the neuro franchise tracking relative to expectations? - Management stated that the neuro franchise is on plan and expects significant growth throughout the year, with potential upside from new product launches [34] Question: What is the expected mix of MRI versus OR procedures in the future? - Management indicated that while MRI procedures currently dominate, there is potential for OR procedures to grow faster as new therapies are introduced [40] Question: What is the status of GLP certification and customer interest? - Management confirmed that they are on track for GLP certification by the end of the year and noted strong interest from pharma partners for studies once certified [42][46]

Financial Performance - Total revenue for Q1 2025 was $8.485 million, a 11.1% increase from $7.639 million in Q1 2024[20] - Product revenue increased to $5.291 million in Q1 2025, up 45.5% from $3.635 million in Q1 2024[20] - Gross profit for Q1 2025 was $5.132 million, compared to $4.525 million in Q1 2024, reflecting a gross margin improvement[20] - Net loss for Q1 2025 was $6.026 million, compared to a net loss of $4.146 million in Q1 2024, indicating increased operational costs[20] - Total revenue for the three months ended March 31, 2025, was $8.485 million, an increase of 11.1% compared to $7.639 million for the same period in 2024[71] Research and Development - Research and development costs rose to $3.379 million in Q1 2025, up 28.8% from $2.625 million in Q1 2024[20] - Research and development share-based compensation increased to $484,000 in Q1 2025, up from $337,000 in Q1 2024, reflecting a 43.7% rise[94] Cash and Liquidity - Cash and cash equivalents decreased to $12.387 million at the end of Q1 2025 from $20.104 million at the end of Q4 2024[25] - Cash and cash equivalents were $12.4 million as of March 31, 2025, down from $20.1 million at December 31, 2024, reflecting a decrease of 38.3%[78] - The company has evaluated its ability to continue as a going concern and determined that existing cash balances are sufficient to support operations for at least the next twelve months[34] Assets and Liabilities - Total assets decreased to $30.070 million as of March 31, 2025, down from $39.189 million as of December 31, 2024[18] - Total liabilities decreased to $10.083 million as of March 31, 2025, down from $13.800 million as of December 31, 2024[18] Customer and Revenue Recognition - The company recognizes revenue primarily from product sales, including neurosurgery navigation products and service revenue from development services and consultation[43] - As of March 31, 2025, one customer accounted for 12% of accounts receivable, while two customers represented 24% of accounts receivable as of December 31, 2024[61] - A pharmaceutical customer accounted for 9% of total sales for the three-month periods ended March 31, 2025, and 2024[62] - The company recognized approximately $0.8 million of revenue from deferred revenue during the three months ended March 31, 2025[75] Offerings and Financing - The company completed a follow-on public offering in March 2024, raising approximately $16.2 million from the sale of 2,653,848 shares of common stock[36] - The company has an At-the-Market Equity Offering Sales Agreement allowing for the sale of up to $50 million in common stock, but no shares have been issued under this agreement as of March 31, 2025[36] - The company repaid the remaining $10 million under a Securities Purchase Agreement in August 2024, which had raised gross proceeds of $25 million[37] - The company completed a public offering in March 2024, raising net proceeds of approximately $16.2 million from the sale of 2,653,848 shares at a price of $6.50 per share[91] - The company has not issued any shares under the At-The-Market (ATM) Agreement, which allows for sales of up to $50 million in common stock[92] - The company may sell notes up to an aggregate principal amount of $105 million under a note purchase agreement, with a minimum interest rate of 8.25%[106] Inventory and Deferred Revenue - Inventory totaled $6.689 million as of March 31, 2025, compared to $6.966 million at December 31, 2024, a decline of 4.0%[80] - Deferred revenues decreased to $1.975 million as of March 31, 2025, down from $2.557 million at December 31, 2024, indicating a reduction of 22.7%[75] - The company expects to recognize approximately 79% of the remaining performance obligations, valued at $1.7 million, over the next twelve months[76] Stock and Compensation - Share-based compensation expense for Q1 2025 totaled $1,908,000, an increase of 27% from $1,504,000 in Q1 2024[94] - The total unrecognized compensation expense as of March 31, 2025, is $13,499,000, with a weighted-average recognition period of 1.99 years[96] - The company has 1,352,615 stock options outstanding as of March 31, 2025, with an average exercise price of $6.16 and an intrinsic value of $8,897,000[97] - Restricted Stock Units (RSUs) granted in Q1 2025 totaled 541,771, with an average grant date fair value of $13.55[100] Business Operations - The company operates in one reportable segment, primarily generating revenue in the United States[101] - The company has not recorded significant foreign currency sales and does not currently engage in hedging transactions[158] - The company has over 60 biologics and drug delivery customers currently evaluating or using its products and services[32] - The ClearPoint Prism Neuro Laser Therapy System was commercialized in 2022, marking a significant product development milestone[31] Accounting Standards - The company is currently evaluating the impact of new accounting standards on its consolidated financial statements, including ASU 2023-07 and ASU 2023-09[65][68]

[ClearPoint Neuro First Quarter 2025 Results](index=1&type=section&id=ClearPoint%20Neuro%20First%20Quarter%202025%20Results) [First Quarter 2025 Highlights](index=1&type=section&id=First%20Quarter%202025%20Highlights) ClearPoint Neuro achieved record Q1 2025 revenue of $8.5 million, an 11% increase, driven by a 104% surge in consumable products and strategic advancements Q1 2025 Key Performance Indicators | Metric | Q1 2025 | Change (YoY) | | :--- | :--- | :--- | | Total Revenue | $8.5 million | +11% | | Total Consumable Product Revenue | $5.3 million | +104% | | Cash and Cash Equivalents (as of Mar 31) | $12.4 million | N/A | - The CEO highlighted that the company is entering a "Fast Forward phase," with foundational investments in biopharma partnerships, operating room navigation, and laser therapy now yielding significant growth[3](index=3&type=chunk) - The company secured a long-term credit facility and an equity investment from Oberland Capital, enhancing balance sheet flexibility to achieve strategic goals[3](index=3&type=chunk) - Received FDA Clearance for the ClearPoint 3.0 Software, which is now in Full Market Release and contributing to revenue and case volume growth[4](index=4&type=chunk) [Financial Results – Quarter Ended March 31, 2025](index=2&type=section&id=Financial%20Results%20%E2%80%93%20Quarter%20Ended%20March%2031%2C%202025) Q1 2025 saw 11% revenue growth to $8.5 million and improved gross margin to 60%, but operating expenses rose 29% to $11.3 million, widening the operating loss to $6.2 million [Revenue Analysis](index=2&type=section&id=Revenue%20Analysis) Revenue growth was driven by a 70% increase in Neurosurgery navigation and therapy sales and a 9% rise in Biologics and drug delivery, while Capital equipment revenue declined 63% Q1 Revenue Breakdown (in millions) | Revenue Segment | Q1 2025 | Q1 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | **Total Revenue** | **$8.5** | **$7.6** | **+11%** | | Biologics and Drug Delivery | $4.7 | $4.3 | +9% | | Neurosurgery Navigation and Therapy | $3.3 | $1.9 | +70% | | Capital Equipment and Software | $0.5 | $1.4 | -63% | - The increase in Neurosurgery revenue was driven by higher sales for new product offerings and an expanded customer base[8](index=8&type=chunk) - The decrease in Capital equipment revenue was primarily attributed to the timing of installations[9](index=9&type=chunk) [Profitability and Expenses](index=2&type=section&id=Profitability%20and%20Expenses) Gross margin improved to 60%, but operating expenses increased 29% to $11.3 million due to higher personnel and R&D costs, resulting in a net loss of $6.0 million Q1 Profitability Metrics (in millions, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Gross Profit | $5.1 | $4.5 | | Gross Margin | 60% | 59% | | Operating Expenses | $11.3 | $8.7 | | Operating Loss | ($6.2) | ($4.2) | | Net Loss | ($6.0) | ($4.1) | | Net Loss Per Share | ($0.22) | ($0.16) | - The **29% increase in operating expenses** was mainly due to higher personnel-related costs, increased product development, a higher allowance for credit losses, and greater professional and regulatory fees[11](index=11&type=chunk) [Financial Position](index=2&type=section&id=Financial%20Position) Cash and cash equivalents decreased to $12.4 million by March 31, 2025, primarily due to $6.2 million in cash used for operating activities Cash and Cash Equivalents (in millions) | Date | Amount | | :--- | :--- | | March 31, 2025 | $12.4 | | December 31, 2024 | $20.1 | - The decrease in cash was driven by **$6.2 million used in operating activities** and **$1.3 million for tax payments** on equity awards[12](index=12&type=chunk) [Business Outlook](index=2&type=section&id=Business%20Outlook) The company reaffirmed its full-year 2025 revenue guidance, projecting total revenue between $36.0 million and $41.0 million - Full year 2025 revenue outlook is reaffirmed to be between **$36.0 million and $41.0 million**[5](index=5&type=chunk) [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) Unaudited consolidated financial statements for Q1 2025 show a net loss of $6.0 million, total assets of $30.1 million, and a $7.7 million net decrease in cash [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Q1 2025 revenue was $8.5 million, resulting in a net loss of $6.0 million, or ($0.22) per share, compared to a $4.1 million loss in Q1 2024 Consolidated Statements of Operations (Unaudited, in thousands, except per share data) | | For the Three Months Ended March 31, | | :--- | :--- | :--- | | | **2025** | **2024** | | **Total revenue** | **$8,485** | **$7,639** | | Gross profit | $5,132 | $4,525 | | Operating loss | $(6,163) | $(4,216) | | **Net loss** | **$(6,026)** | **$(4,146)** | | **Basic and diluted net loss per share** | **$(0.22)** | **$(0.16)** | | Weighted average shares outstanding | 27,718,918 | 25,452,096 | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets were $30.1 million, down from $39.2 million, with total liabilities at $10.1 million and equity at $20.0 million Consolidated Balance Sheet Highlights (Unaudited, in thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $12,387 | $20,104 | | Total current assets | $24,214 | $33,363 | | **Total assets** | **$30,070** | **$39,189** | | Total current liabilities | $6,866 | $10,353 | | **Total liabilities** | **$10,083** | **$13,800** | | **Total stockholders' equity** | **$19,987** | **$25,389** | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Q1 2025 saw $6.2 million net cash used in operating activities, $0.2 million in investing, and $1.4 million in financing, leading to a $7.7 million net decrease in cash Consolidated Statement of Cash Flows Highlights (Unaudited, in thousands) | | For the Three Months Ended March 31, | | :--- | :--- | :--- | | | **2025** | **2024** | | Net cash flows from operating activities | $(6,172) | $(3,840) | | Net cash flows from investing activities | $(183) | $— | | Net cash flows from financing activities | $(1,362) | $16,053 | | **Net change in cash and cash equivalents** | **$(7,717)** | **$12,213** | | Cash and cash equivalents, end of period | $12,387 | $35,353 |

Shares of ClearPoint Neuro, Inc. (CLPT) have gained 18.2% over the past four weeks to close the last trading session at $13.64, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $27.67 indicates a potential upside of 102.9%.The average comprises three short-term price targets ranging from a low of $25 to a high of $30, with a standard deviation of $2.52. While the lowest estimate ...

Group 1 - ClearPoint's share price has been volatile, but there is a steady flow of positive news regarding its business fundamentals [1] - Richard Durant leads Narweena, an asset manager focused on identifying market dislocations due to poor long-term business prospects understanding [1] - Narweena aims for excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with barriers to entry [1] Group 2 - Narweena's research emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and long-term investment horizon [1] - The firm focuses on smaller cap stocks and markets where competitive advantages are not immediately apparent [1] - An aging population with low growth and stagnating productivity is expected to create new investment opportunities, contrasting with past trends [1] Group 3 - Many industries may face stagnation or secular decline, potentially improving business performance due to reduced competition [1] - Other businesses may encounter rising costs and diseconomies of scale, affecting their performance negatively [1] - The economy is increasingly dominated by asset-light businesses, leading to a declining need for infrastructure investments over time [1] Group 4 - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] - Richard Durant holds undergraduate degrees in engineering and finance and an MBA, and has passed the CFA exams [1]

Group 1 - ClearPoint's fourth quarter results were somewhat soft, which is not surprising given that many of the company's growth initiatives are still ramping [1] - Guidance for ClearPoint was also weak, partly due to the timing of events [1] Group 2 - Narweena, an asset manager led by Richard Durant, focuses on finding market dislocations resulting from a poor understanding of long-term business prospects [1] - Narweena believes excess risk-adjusted returns can be achieved by identifying businesses with secular growth opportunities in markets with barriers to entry [1] - The research process at Narweena is centered on company and industry fundamentals to uncover unique insights [1] Group 3 - Narweena has a high risk appetite and a long-term investment horizon, targeting deeply undervalued stocks, particularly in smaller cap stocks and markets with less obvious competitive advantages [1] - The firm anticipates that an aging population with low growth and stagnating productivity will create new investment opportunities [1] - Many industries may face stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] Group 4 - There is a trend of increasing dominance of asset-light businesses, leading to a declining need for infrastructure investments over time [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premia [1] Group 5 - Richard Durant holds undergraduate degrees in engineering and finance from the University of Adelaide and an MBA from Nanyang Technological University [1] - Durant has passed the CFA exams, indicating a strong background in finance [1]

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings. Welcome to ClearPoint Neuro, Inc. Fourth Quarter and Full Year 2024 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Opera ...

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post a loss of $0.17 per share when it actually produced a loss of $0.18, delivering a surprise of -5.88%.Over the last four quarters, the company has ...